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Abstract
Background: Cdc7 is a widely expressed protein kinase implicated in cell division, cell cycle checkpoint
mechanisms and cancer progression. Recently, it has been suggested as a target for anti-cancer therapy.
Methods: To determine the relationship of Cdc7 protein expression with tumor phenotype, molecular features and
prognosis, 1800 colorectal carcinomas were analyzed by immunohistochemistry on a tissue microarray.
Results: Cdc7 expression was considered negative in 33.6 %, weak in 57.2 % and strong in 9.2 % of 1711
interpretable CRCs. Loss of Cdc7 expression was significantly associated with high tumor stage (p < 0.0001) and
high tumor grade (p = 0.0077), but was unrelated to the nodal status (p = 0.5957). Moreover, a link between Cdc7
expression and the tubular histological tumor type was seen (p < 0.0001). p53 and Cdc7 expression were
significantly linked to each other (p = 0.0013). In a multivariate survival analysis, strong Cdc7 expression of CRC was
an independent marker of improved patient survival (p = 0.0031).
Conclusion: Our data show that Cdc7 is highly expressed in CRC and a potential therapeutic target in a subset of
cancers with high p53 expression. Moreover, our findings strongly argue for a clinical utility of Cdc7
immunostaining as an independent prognostic biomarker in colorectal cancer enabling to select patients for
adjuvant treatment.
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Background
Colorectal cancer (CRC) is the fourth most common
malignant disease with over 1 million novel cases and
over 500.000 deaths each year worldwide [1].
Although recent advances in the management of the
disease have improved outcomes, CRC remains the sec-
ond leading cause of cancer-related death in Western
countries [1]. In advanced metastatic colorectal cancer
(mCRC), surgery alone is not curative and therefore
adjuvant chemotherapy is needed. There is much promise
in targeted anti-cancer therapies. Encouraged by the suc-
cess of targeted therapies directed against key molecules
of cell growth like the HER2, EGFR, or KIT tyrosine
kinase receptors, researchers have extended their survey
for promising candidate targets to genes that participate
in the control of cell division and replication. Such genes
represent the most downstream effectors of growth
signaling pathways and therefore it is believed that their
inhibition will be effective in a broad range of different
tumor types characterized by rapid cell proliferation.
The cell division cycle 7- (Cdc7) related protein kinase
is an enzyme that is essential for DNA replication in
human cells [2, 3]. Overexpression of Cdc7 and its protein
regulator Dbf4 has been reported in many human tumors
[4], including ovarian cancer [5], melanoma [6, 7], diffuse
large B-cell lymphoma [8], oral squamous cell carcinoma
[9] and breast cancer [10]. Cdc7 and Dbf4 overexpression
are reported to cause cell-cycle arrest in S phase and it
has been hypothesized that increased Cdc7 activity may
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aid recovery or repair of stalled replication forks to
enhance survival of tumor cells [11]. Therefore, it can be
assumed that alterations in Cdc7/Dbf4 protein activity
during tumorigenesis may have important consequences
for tumor cell survival, underlining the potential of Cdc7
as an anticancer target. High expression of Cdc7 protein
correlates with poor prognosis in patients with diffuse
large B-cell lymphoma and is a marker of resistance to
DNA-damaging agents in oral squamous cell carcinoma
[9, 8]. Preclinical data show that Cdc7 is a novel and
promising target for tumor-cell killing, as has been shown
with different inhibitors [12–15]. Little is known about the
prevalence and significance of Cdc7 in colorectal cancer.
To study the potential role of Cdc7 in CRC a tissue
microarray containing 1.800 tumor samples with clinical
follow-up data was analyzed. Our data suggest that Cdc7
overexpression may point out a small but significant
subset of immunohistochemically p53-positive CRC that
could benefit from anti-Cdc7 treatment.
Methods
Patients and tissue microarray (TMA) construction
Two different TMAs with a total of 1800 CRC samples
were included in this study. The first TMA was manu-
factured from resection specimens of 1420 CRC patients
at the Institute of Pathology of the University Hospital
of Basel. None of the patients received preoperative neo-
adjuvant or adjuvant therapy. Raw survival data were
obtained from the responsible physicians for all of the
1420 patients. The median follow up time was 46 months
(range 1–152 months). The second TMA included sam-
ples from 380 CRC patients, whose tumor resection
specimens were examined at the Institute of Pathology
of the University Medical Center Hamburg-Eppendorf.
Also for this TMA, raw survival data were available for
all of the 380 patients with a median follow up period of
36 months (range 1–179 months). TMA construction
was as described [16]. In brief, hematoxylin and eosin-
stained sections were made from each block to define rep-
resentative tumor regions. Tissue cylinders with a diameter
of 0.6 mm were then punched from tumor areas of each
“donor” tissue block using a home-made semi-automated
precision instrument and brought into empty recipient
paraffin blocks. Four μm sections of the resulting TMA
blocks were transferred to an adhesive coated slide system
(Instrumedics Inc., Hackensack, New Jersey). Patient infor-
mation and clinical data as age, sex, localization and type
of the tumor, pTNM-stage and carcinoma grade were
retrospectively retrieved from clinical and pathological
databases (Table 1). All tumors were re-classified by two
pathologists (LT, AM). Follow-up data were obtained from
local cancer register boards or via attending physicians. For
statistical analyses, tumor localizations were grouped as
follows: right-sided cancer (cecum, ascending colon), cancer
of the transverse colon, cancer of the left-sided colon (de-
scending colon, sigmoid colon) and rectum.
The utilization of tissues and clinical data was according
to the Hamburger Krankenhaus Gesetz (§12 HmbKHG)
and approved by our local Ethical Committee.
Cdc7 immunohistochemistry
Standard indirect immunoperoxidase procedures were
used for the detection of Cdc7 (abcam, clone SPM171,
dilution 1:150). Sections were heated in an autoclave at
121 °C for 10 min in citrate buffer (pH 9.0). Diamino-
benzidine was used as a chromogen and sections were
counterstained with Mayer’s hematoxylin. Immunostain-
ing was typically nuclear. For tumor tissue the percentage
of positive cells was estimated and the staining intensity
was recorded as 1+, 2+ or 3+. For statistical analyses, the
staining results were categorized into three groups as pre-
viously described [17]. Tumors without any staining were
considered “negative”. Tumors showing at least weak
Cdc7 staining were considered “positive”. Tumors with 1+
or 2+ positivity in up to 50 % or 3+ positivity in up to
20 % of cells were considered “weakly positive”. Tumors
with 2+ staining in >50 % or 3+ staining in >20 % of cells
were considered “strongly positive”. The molecular data-
base attached to this TMA contained results on p53 ex-
pression in 1800 cancers.
Table 1 Clinical and pathological features of colorectal cancers
Clinical/pathological features n available
Gender Female 858
Male 853
Age Mean: 69 (29 – 96)
Tumor grade G1 29
G2 1505
G3 177




Nodal status pN0 889
pN1 458
pN2 364
Tumor type Tubular carcinoma 1644
Mucinous carcinoma 59
Others 8




Total number of patients 1711
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Statistics
Statistical calculations were performed with JMP® 10.0.2
software (2012 SAS Institute Inc., NC, USA). Contin-
gency tables and the chi2-test were performed to search
for associations between molecular parameters and
tumor phenotype. Survival curves were calculated ac-
cording to Kaplan-Meier. The Log-Rank test was ap-
plied to detect significant survival differences between
groups. Cox proportional hazards regression analysis
was performed to test the statistical independence and
significance between pathological and clinical variables.
Results
Technical issues
A total of 1711 (95.1 %) of tumor samples were interpretable
in our TMA analysis (Table 1). Reasons for non-informative
cases (289 spots; 4.9 %) included lack of tissue samples or
absence of unequivocal cancer tissue in the TMA spot.
Cdc7 expression in colorectal cancer
Cdc7 expression was considered negative in 33.6 %,
weak in 57.2 % and strong in 9.2 % of 1711 interpretable
CRCs. Representative images of Cdc7 IHC are given in
Fig. 1a - c. Loss of Cdc7 expression was significantly
associated with high tumor stage (p < 0.0001) and high
tumor grade (p = 0.0077), but was unrelated to the nodal
status (p = 0.5957, Table 2). Moreover, a link between
Cdc7 expression and the tubular histological tumor type
was seen (Table 2, p < 0.0001).
Association with tumor localization
Cdc7 expression levels were not related to tumor localiza-
tion (Table 2, p = 0.2093).
Association with p53 expression
p53 expression was significantly linked to Cdc7 expres-
sion (Table 2, p = 0.0013). Representative images of p53
IHC are given in Fig. 1d - f.
Survival analysis
As expected, high tumor grade and stage as well as
advanced nodal status were associated with poor patient
survival (Fig. 2a-c; p < 0.0001 each). Strong Cdc7 expres-
sion in CRC was significantly related to improved pa-
tient survival compared to cases with loss of Cdc7
expression (Fig. 2d; p = 0.0003). Immunohistochemical
p53 status in the CRC did not show any impact on
survival (p = 0.3735; data not shown).
Multivariate analysis
In a multivariate analysis including all parameters that were
significantly associated with survival on univariate analysis
(pT, pN, tumor grade Fig. 2a-c, and tumor localization;
data not shown), Cdc7 expression retained significance as
an independent prognostic marker (Table 3, p = 0.0031).
Discussion
The results of this study show that in CRC strong Cdc7
expression is an independent favorable prognostic marker
Fig. 1 Representative images of immunohistochemical Cdc7 and p53 expression in colorectal cancer: a Cdc7 negative; b Cdc7 low and c Cdc7
high expression, d p53 negative; e p53 low and f p53 high expression, magnification 50 x each
Melling et al. Diagnostic Pathology  (2015) 10:125 Page 3 of 7
and significantly linked to immunohistochemical p53
positivity. Cdc7 expression was found in 66.4 % of all in-
terpretable CRCs, and it was typically described as weak
in normal tissue. Only few reports on results of Cdc7 ex-
pression in CRC exist. Chen et al. reported a significantly
higher mRNA and protein expression of Cdc7 in 39 colo-
rectal cancers as compared to tumor-adjacent normal
colorectal tissue [18] and colorectal cancer is among the
cancer types that shows the strongest up regulation in
Cdc7 expression as determined from data obtained by
mining Oncomine and Gene Expression Omnibus data-
bases. Bonte et al. examined Cdc7 expression in an array
of human malignancies, including colon cancer where
they found low Cdc7 expression in 2 and high Cdc7 ex-
pression in 8 of 10 cases [4].
The percentage of CRC cases with "strong" Cdc7
staining in our study is 9.2 %. This may be attributable
to a mismatch between mRNA and protein levels, but it
is more likely caused by immunohistochemistry condi-
tions. It is well known that varying antibody dilutions
lead to significant changes in the rate of positive cases
[19]. This is all the more expected in the case of ubiqui-
tously expressed proteins, such as Cdc7.
Various functional studies had previously demonstrated
that Cdc7 is essential for cell proliferation [20, 21]. The
strong association between Cdc7 and p53 overexpression
found in our study was therefore expected, although p-
values may appear stronger than the absolute values
imply, due to the high caseload (e.g. p53 positive vs p53
negative 11.7 % vs 9.8 %; p = 0.0013). A previous study
has shown that a p53-dependent pathway in normal fi-
broblasts actively prevents progression through a lethal
S phase in the absence of sufficient Cdc7 kinase. In con-
trast, Cdc7 and p53-depleted tumor cells do not elicit a ro-
bust checkpoint response. Therefore, it has been suggested
that p53 is required for cell viability in Cdc7 deficient cells
[22]. Moreover, it has been reported that ATR-dependent
activation of p38 MAP kinase is responsible for apoptotic
cell death in Cdc7-depleted cells [23]. In CRC, up to 42 %
of the cases show p53-mutations with a strong inverse cor-
relation between p53 alterations and MSI [24]. Thus, we
hypothesize that Cdc7 inhibition may serve as a new ther-
apeutical approach in a subgroup of p53-deficient CRC,
which are predominately localized in the left colon [24].
In our study, Cdc7 overexpression proved to be an
independent marker for good prognosis in CRC. This
finding is in contrast to studies on other cancer types
where Cdc7 overexpression is linked with worse progno-
sis. For example, Cheng et al. reported in their study on
oral squamous cell carcinoma (OSCC) that Cdc7 over-
expression is an unfavorable prognostic marker and
suggested Cdc7 overexpression contributing to the re-
sistance to DNA-damaging agents [9].
In another recent study of our group on more than 2.100
breast cancers, Cdc7 expression was seen in 57 % of the
cases. Comparable to what was found in CRC, in breast
cancer high levels of Cdc7 expression were also significantly
related to high tumor grade, high Ki67 expression and p53
overexpression. Although the IHC scoring system was
slightly different in this breast cancer study (4 categories vs
3 categories as described earlier) [17], the percentages of
Cdc7 negative, weakly and strongly positive breast cancers
were similar to our findings in CRC [10].
However, when comparing Cdc7 expression and tumor
grade and stage, results in both studies opposed each other.
Whereas in CRC low levels of Cdc7 expression were signifi-
cantly associated with high tumor grade and stage, in breast
cancer high levels of Cdc7 expression were linked with
higher tumor grade and stage [10]. The reason for this dis-
crepancy is unknown but description of variable biological
roles of one biomarker in different tumor entities is not un-
common. For example, AQP5 expression is associated with
Table 2 Cdc7 IHC, clinico-pathological and molecular parameters
in CRC
Cdc7
Parameter Negative (%) Weak (%) Strong (%) p-value
All cancers 1711 33.6 57.2 9.2
Tumor stage
pT1 75 25.3 53.3 21.4
pT2 270 24.1 64.8 11.1
pT3 1104 34.6 57.5 7.9
pT4 262 41.6 48.9 9.5 <0.0001
Nodal status
pN0 889 32.2 58.7 9.1
pN1 458 36.2 55.0 8.8
pN2 364 33.8 56.0 10.2 0.5957
Grading
G1 29 34.5 37.9 27.6
G2 1505 32.8 58.3 8.9
G3 177 40.7 50.3 9.0 0.0077
Tumor localization
Right 414 37.2 53.9 8.9
Transverse 149 37.6 54.4 8.0
Left 514 31.6 60.2 8.2
Rectum 637 30.8 58.3 10.9 0.2093
Histological type
Tubular 1644 33.5 57.6 8.9
Mucinous 59 37.3 50.8 11.9 <0.0001
p53
Negative 530 36.6 53.6 9.8
Positive 376 25.3 63.0 11.7 0.0013
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poor prognosis in breast cancer [25–27], hepatocellular car-
cinoma [28], colorectal carcinoma [29, 30], chronic myelog-
enous leukemia [31], lung cancer [32, 33], ovarian cancer
[34, 35], cervical cancer [36] and oral squamous cell carcin-
oma [37], but to better outcome in gallbladder [38] and bil-
iary tract cancer [39].
Furthermore, some biomarkers, such as GSK3ß, are
known to play both tumor suppressive and promoting
roles depending on the microenvironment It has, thus,
been suggested that GSK3ß function may switch be-
tween tumor promotion and suppression depending on
cell properties and the stage of tumorigenesis [40].
Therefore, varying oncogenic properties of Cdc7 might
also be attributable to differing molecular backgrounds
in various cancer types.
Of note, Cdc7 has been shown to represent a potent
and highly specific anticancer target in p53-mutant,
Her2-overexpressing and triple-negative breast cancers
[41]. Based on these findings, a number of different Cdc7
kinase inhibitors which showed anti-tumor activity have
been developed recently [12–14]. Our data show that
Cdc7 is expressed in the majority of colorectal cancers
and therefore could serve as a potential therapy target.
It is well known that immunostaining of p53 can serve
as a surrogate marker for p53 mutations in cancer [42].
Thus, CRC, which show p53 overexpression are likely to
harbor p53 mutations and therefore may be susceptible
to anti-Cdc7 therapy [22].
However, experimental and clinical studies examining
the efficacy of Cdc7 kinase inhibitors in CRC are still
needed as well as data on Dbf4 protein expression, since
colorectal cancers have been shown to have strong levels
of Dbf4 mRNA expression and Dbf4 expression levels
were uniformly high among most colorectal tumors
(Bonte et al.). This data could well be recruited by a
TMA approach similar to ours.
Fig. 2 Association between survival and a Tumor stage, p < 0.0001; b Nodal status, p < 0.0001; c Tumor grade, p < 0.0001 and d Cdc7 expression
(Cdc7 strong-blue, Cdc7 weak-green, Cdc7-negative-red); p = 0.0003
Table 3 Multivariate analysis of Cdc7 in colorectal cancer
p-value
n cases pT pN Grading Tumor localization Cdc7
1711 <0.0001 <0.0001 0.0008 0.8200 0.0031
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Conclusion
In summary, our data show that Cdc7 is highly expressed
in CRC and may represent a potential therapeutic target
in a subset of cancers with high p53 expression.
Finally, our findings strongly argue for a clinical utility
of Cdc7 immunostaining as an independent prognostic
biomarker in colorectal cancer enabling to select patients
for adjuvant treatment.
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